SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Potential Offer

6 Sep 2010 15:14

RNS Number : 2239S
Silence Therapeutics PLC
06 September 2010
 



 

 

FOR IMMEDIATE RELEASE

 

Potential Offer

 

London, 6 September, 2010 - Silence Therapeutics plc (AIM: SLN) notes the recent share price movement and announces that it has received an approach which may or may not lead to an offer for the Company. A further announcement will be made in due course.

 

For further information, please contact:

 

Silence Therapeutics

Phil Haworth, CEO +1 (650) 855-1514

p.haworth@silence-therapeutics.com

NOMAD

Nomura Code Securities

Richard Potts / Jonathan Senior

+44 20 7776 1200

 

European media and investor enquiries:

M:Communications +44 20 7920 2342

Mary-Jane Elliott / Emma Thompson

 

US media and investor enquiries:

Vida Communication +44 (415) 675-7400

Tim Brons (media)

tbrons@vidacommunication.com 

or

Stephanie Diaz (investors)

sdiaz@vidacommunication.com

 

The City Code on Takeovers and Mergers (the "City Code")

 

1) Rule 2.10 of the City Code

 

In accordance with Rule 2.10 of the City Code, the Company confirms that it has 279,891,452 ordinary shares of 1p each in issue under the ISIN code GB0008433350.

 

2) Disclosure requirements of the Takeover Code (the "Code")

 

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any paper offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any paper offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
SPMZQLFBBKFBBBK
Date   Source Headline
28th Apr 20107:00 amPRNSilence (AIM: SLN) to Release Prelim Results on April 29
21st Apr 20107:00 amPRNSilence (AIM:SLN), AstraZeneca Extend RNAi Collaboration
15th Apr 20107:00 amPRNSilence Therapeutics (AIM: SLN) Appoints New CFO
13th Apr 20107:00 amPRNSilence(AIM:SLN) Integrates Assets from Intradigm Merger
30th Mar 20107:02 amPRNResearch Update
19th Mar 20103:27 pmPRNHolding(s) in Company
1st Mar 20107:00 amPRNDirectorate Change
15th Feb 20107:00 amPRNDirector/PDMR Shareholding
12th Feb 20103:28 pmPRNSenior Independent Director
12th Feb 20101:28 pmPRNNotification of Results
28th Jan 20103:00 pmPRNTotal Voting Rights
8th Jan 20101:00 pmPRNHolding(s) in Company
5th Jan 20101:35 pmPRNAcquisition and Issue of Equity
4th Jan 201012:40 pmPRNEGM Statement
17th Dec 200912:05 pmPRNStatement re Posting of Document
16th Dec 20095:03 pmRNSSchedule 1 - Silence Therapeutics plc
16th Dec 200912:00 pmRNSRestoration - Silence Therapeutics plc
16th Dec 200912:00 pmPRNAcquisition
14th Dec 200912:45 pmPRNAGM Statement
20th Nov 20097:00 amPRNNotice of AGM
15th Oct 20097:05 amPRNPatent Update
2nd Oct 20094:55 pmPRNCorrection : Half-yearly Report
30th Sep 20097:00 amPRNHalf-yearly Report
29th Sep 200910:15 amPRNTemporary Suspension
29th Sep 200910:15 amRNSSuspension - Silence Therapeutics plc
17th Sep 20097:00 amPRNNotice of Results
1st Sep 20094:40 pmRNSSecond Price Monitoring Extn
1st Sep 20094:35 pmRNSPrice Monitoring Extension
28th Aug 20094:25 pmPRNHolding(s) in Company
27th Aug 20094:40 pmRNSSecond Price Monitoring Extn
27th Aug 20094:35 pmRNSPrice Monitoring Extension
27th Aug 20097:00 amPRNRe Agreement
26th Aug 200911:30 amPRNHolding(s) in Company
14th Jul 200911:30 amPRNIssue of Equity
1st Jul 20094:40 pmRNSSecond Price Monitoring Extn
1st Jul 20094:35 pmRNSPrice Monitoring Extension
24th Jun 20097:00 amPRNAnnual Financial Report
23rd Jun 20097:00 amPRNResearch Update
19th Jun 20094:35 pmRNSPrice Monitoring Extension
3rd Jun 200912:05 pmPRNStatement re Approval for Clinical Trial
22nd May 20094:40 pmRNSSecond Price Monitoring Extn
22nd May 20094:35 pmRNSPrice Monitoring Extension
12th May 20094:40 pmRNSSecond Price Monitoring Extn
12th May 20094:35 pmRNSPrice Monitoring Extension
11th May 20094:40 pmRNSSecond Price Monitoring Extn
11th May 20094:35 pmRNSPrice Monitoring Extension
7th May 20094:40 pmRNSSecond Price Monitoring Extn
7th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20094:51 pmRNSSecond Price Monitoring Extn
5th May 20094:46 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.